Is PHVS or PLRX more undervalued in 2026?

CirclFi compares Pharvaris N.V. (PHVS) and Pliant Therapeutics, Inc. (PLRX) using 13 institutional-grade valuation models. PHVS has a Quality of Company score of 3.9/10 while PLRX scores 4.3/10.

Which is a better buy — PHVS or PLRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PHVS and PLRX valuations compare?

PHVS at $29.86 and PLRX at $1.25 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PHVS vs PLRX Valuation Comparison 2026 — Intrinsic Value Analysis

PHVS

Biotechnology

Pharvaris N.V.

Quality

3.9

out of 10

Value Trap

SAFE

Price

$29.86

Last close

Models

7/13

Active

PLRX

Biotechnology

Pliant Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

LOW

Price

$1.25

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	PHVS Fair Value	PHVS Upside	PLRX Fair Value	PLRX Upside
Bayesian DCF	Intrinsic	$10.81	-63.8%	$0.12	-90.6%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$4.54	-84.8%	$3.22	+157.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PHVS vs PLRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PHVS vs PLRX — Which Stock Is More Undervalued?

PLRX scores higher with a 4.3/10 quality rating vs PHVS's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pharvaris N.V. (PHVS) and Pliant Therapeutics, Inc. (PLRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PHVS currently trades at $29.86 with a QOC of 3.9/10, while PLRX trades at $1.25 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).